Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population.

Kozlowski, Steven; Flowers, Natasha; Birger, Noy; Wernecke, Michael; MaCurdy, Thomas E; Kelman, Jeffrey A; Graham, David J

Kozlowski, Steven; Flowers, Natasha; Birger, Noy; Wernecke, Michael; MaCurdy, Thomas E; Kelman, Jeffrey A; Graham, David J.

Afiliación

Kozlowski S; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Steven.Kozlowski@fda.hhs.gov.
Flowers N; Acumen, LLC, Burlingame, CA, USA.
Birger N; Acumen, LLC, Burlingame, CA, USA.
Wernecke M; Acumen, LLC, Burlingame, CA, USA.
MaCurdy TE; Acumen, LLC, Burlingame, CA, USA.
Kelman JA; Centers for Medicare & Medicaid Services, Washington, DC, USA.
Graham DJ; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

J Gen Intern Med ; 36(7): 2170-2173, 2021 07.

Article en En | MEDLINE | ID: mdl-32578017

Asunto(s)

Antirreumáticos; Biosimilares Farmacéuticos; Humanos; Infliximab; Medicare; Resultado del Tratamiento; Estados Unidos/epidemiología

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antirreumáticos / Biosimilares Farmacéuticos País/Región como asunto: America do norte Idioma: En Revista: J Gen Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google